Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show

A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler, under-the-skin injection is equally effective as the currently approved intravenous infusion, according to study results presented Wednesday by its maker, Eisai.

But hopes that the subcutaneous injection would also cause lower rates of brain swelling and bleeding — the drug’s most worrisome side effects — were not borne out in the study.

The findings were presented during an evening symposium at the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) meeting, underway in Boston.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In